Target: Trk family | Disease State: Cancer

Introduction / Brief Description

Vitrakvi® (larotrectinib / LOXO-101) is an oral and selective inhibitor of tropomyosin receptor kinases (Trk), a family of signaling proteins that are thought to play an important role in cellular communication and tumor growth. Growing research suggests that the NTRK genes, which encode for Trk, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body. Vitrakvi targets Trk, turning off the signaling pathway that allows Trk fusion cancers to grow. In November 2018, the U.S. Food and Drug Administration (FDA) approved Vitrakvi. In July 2013, Array initiated a multi-year license and collaboration agreement with Loxo Oncology for certain Array-invented compounds, including Vitrakvi; LOXO-292, a Ret inhibitor; and LOXO-195, a Trk inhibitor.

In February 2019, Eli Lilly acquired Loxo Oncology. Bayer AG has exclusive rights to Vitrakvi. The licensing agreement between Array and Loxo remains in effect.

Clinical Trials

To learn more about larotrectinib clinical trials, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.

Vitrakvi® is a registered trademark of Bayer AG.